Objectives: This study evaluated the oxazolidinone resistance mechanisms among a global collection of enterococcal clinical isolates. The epidemiology of optrA-carrying isolates and the optrA genetic context were determined.
Introduction
Enterococcus species are considered part of the normal flora of the human gut microbiome. However, these isolates are also opportunistic pathogens broadly implicated in urinary tract infections (UTIs), wound and transplant infections, infections of the heart valve and other prosthetic implants, and septicaemia. 1 Risk factors for developing these infections include age-related colonization, prolonged hospital stay, previous antibiotic use and immunosuppression. Enterococcal infections are second only to staphylococci as a cause of Gram-positive nosocomial infections. 2 These organisms can acquire antimicrobial resistance and VRE remain a challenge, especially Enterococcus faecium. Anti-Gram-positive agents belonging to the oxazolidinone class possess potent activity against clinical pathogens causing infections worldwide, as determined by large surveillance studies. [4] [5] [6] [7] These agents are effective and widely used to treat VRE infections and only a small percentage of linezolid-resistant enterococcal isolates have been reported during surveillance studies. 4, 5, 7 Resistance occurs especially after prolonged administration and local investigations have reported sporadic outbreaks and dissemination of linezolid-dependent Staphylococcus epidermidis isolates in Greece and Germany. [8] [9] [10] [11] [12] [13] [14] [15] Ribosomal mutations, including alterations in oxazolidinone binding sites (23S rRNA and L3 and L4 ribosomal proteins) remain the most common mechanisms of resistance among staphylococci and enterococci. Specifically, G2576T mutation in the V domain of the 23S rRNA gene has been responsible for a resistance phenotype among enterococci. 16 Additional and transferable resistance determinants, such as cfr, cfr(B), cfr(C) and optrA, have been detected as newer mechanisms responsible for decreased susceptibility to linezolid and/or tedizolid. [17] [18] [19] [20] These plasmid-borne resistance genes have been documented in numerous human clinical isolate species in V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. several regions worldwide. 2, 4, [21] [22] [23] [24] [25] [26] [27] [28] [29] In addition, studies have reported on the concomitant detection of cfr and optrA genes in Staphylococcus sciuri and E. faecium. 24 Thus, although oxazolidinones show potent activity (.99% susceptible) against enterococci and Enterococcus faecalis remain susceptible to several agents, the dissemination of optrA in E. faecalis could compromise the clinical utility of the oxazolidinones. In addition, the presence of optrA in the gene pool could further increase its potential to disseminate to other less susceptible species, including E. faecium, which are often only susceptible to oxazolidinones and daptomycin, [30] [31] [32] [33] [34] and already reported by several local studies. This study was conducted to evaluate the oxazolidinone resistance mechanisms among a global collection of enterococcal clinical isolates from the SENTRY Antimicrobial Surveillance Program. Moreover, the epidemiology and genetic context of optrA-carrying isolates were further investigated.
Materials and methods

Bacterial strains
A total of 17 614 E. faecalis and 9034 E. faecium clinical isolates were submitted to the coordinating monitoring laboratory (JMI Laboratories, North Liberty, IA, USA), as part of the SENTRY Antimicrobial Surveillance Program from 2008 to 2016. This programme monitors antimicrobial resistance and prevalence of pathogens causing bloodstream infections, communityacquired pneumonia, pneumonia in hospitalized patients, skin and skin structure infections, UTIs and intra-abdominal infections (six main study protocols). Participating sites follow instructions specific for each protocol to select and include consecutive and unique (one per patient) isolates that are deemed clinically relevant based on local criteria.
Antimicrobial susceptibility testing
Susceptibility testing was performed by broth microdilution methods, according to CLSI recommendations. 35 In addition, the inoculum density was monitored by colony counts to ensure an adequate number of cells for each testing event. Concurrently testing CLSI-recommended quality control reference strains (Staphylococcus aureus ATCC 29213 and E. faecalis ATCC 29212) validated the MICs. 36 MIC interpretations were based on the CLSI M100-S27 and EUCAST documents, when available. 36, 37 Enterococci exhibiting linezolid MIC results of 4 mg/L were selected for further molecular analysis and are presented in this study.
Screening for oxazolidinone resistance mechanisms
Isolates meeting the pre-established screening criteria (linezolid MIC, 4 mg/L) were subjected to the detection of cfr, cfr(B), cfr(C) and optrA and mutations in the 23S rRNA-, L3-and L4-encoding genes by PCR, restriction digests and sequencing as described previously. 18, 38 Amplicons were sequenced on both strands and amino acid sequences compared with those from E. faecalis and E. faecium reference strains.
Characterization of optrA gene context
Genomic DNA of enterococcal isolates carrying optrA was extracted using the Thermo Scientific TM KingFisher TM Flex Magnetic Particle Processor (Cleveland, OH, USA). Total genomic DNA was used as input material for library construction. DNA libraries were prepared using the NexteraXT TM library construction protocol (Illumina, San Diego, CA, USA) following the manufacturer's instructions and sequenced on a MiSeq Sequencer (JMI Laboratories). The coding and surrounding regions of optrA, as well as other antimicrobial resistance determinants and MLST information, were extracted from assembled genomes (SPAdes 9.3.0). The optrA gene cluster sequences of all distinct isolates in this study have been deposited in GenBank (accession numbers MF443367 to MF443388). The optrA gene arrays were analysed and are presented in Figure 1 .
Southern hybridization
Whole genomic DNA was prepared in 1% agarose blocks. DNA was digested by S1 nuclease and I-CeuI enzymes and resolved with PFGE on CHEF DRII (Bio-Rad, Hercules, CA, USA). DNA fragments were transferred to nylon membranes by Southern blotting, probed with a DIG-labelled-optrA-specific probe and developed as per manufacturer's instructions (Roche Diagnostics GmbH, Mannheim, Germany).
Results
A total of 36 E. faecalis and 66 E. faecium met the study screening criteria of a linezolid MIC of 4 mg/L, which constituted 0.38% of surveillance enterococci received between 2008 and 2016 ( Table 1 ). Most E. faecalis isolates exhibited a susceptible phenotype to ampicillin (97.2%-100.0% susceptible), tigecycline (100.0% susceptible) and daptomycin (100.0% susceptible), while marginal activities were observed for the glycopeptides (88.9% susceptible). E. faecium showed high susceptibility rates for tigecycline (95.9% susceptible) and daptomycin (98.6% susceptible; Table 1 ).
The optrA gene was detected in 26 (72.2%) E. faecalis [Tables  1-3 and Figure S1 (available as Supplementary data at JAC Online)]. Among these isolates, one from Thailand and two clonal strains from Panama also carried cfr and cfr(B), respectively (Tables 2 and 3 ). Nine other (25.0%) E. faecalis isolates had G2576T mutations in the 23S rRNA. Six E. faecalis isolates had an alteration in L4 (F101L) in addition to either optrA (two from China and one each from Sweden, Ireland and Thailand) or G2576T (USA). A linezolid resistance mechanism was not identified in one E. faecalis from Ireland (linezolid MIC, 4 mg/L; Table 2 ). All E. faecium isolates showed G2576T mutations, while two isolates from New Orleans (USA) 18 and one from Atlanta (USA) had concomitant presence of cfr(B). One E. faecium isolate showed alteration in L3 (K95T) in addition to G2576T mutation (Table 2) .
Genetic characteristics of OptrA-producing isolates, other resistance determinants and optrA genetic context information are detailed in Table 3 and Figure 1 . Based on the S1 nuclease/I-CeuI Southern blot analysis, optrA was plasmid-located in 22 isolates, while 3 isolates carried this gene in the chromosome (Table 3) . Hybridization signals were obtained on chromosomal DNA and plasmid in one isolate from France. E. faecalis isolates carrying optrA were detected in the SENTRY program as early as 2008 in China and Sweden and in 10 additional countries through 2016 (Table 3 and Figure S1 ). Isolates belonging to the same clonal complex (CC) were observed in distinct regions, such as CC16 isolates that were detected in the USA and Thailand, and CC116 isolates that were detected in China and Ireland (Table 3 ). The CC116 isolates from China and CC86 from Sweden (both from 2008) showed a very similar optrA genetic context (array A; Figure 1 Deshpande et al.
respectively) ( Table 3 and Figure 1 ). One isolate from Ireland yielded a small contiguous sequence (array E). Other isolates from China yielded smaller contiguous sequences and different gene arrangements around optrA (arrays B-D and F). Array F was also observed in an isolate (CC16) from the USA; however, the CC16 isolates from Thailand had a very distinct optrA array (G). A CC59 isolate from Malaysia showed an optrA gene context (array I) similar to F (China/USA), K (USA) and N (Guatemala). Isolates from Taiwan and France showed optrA genes associated with Tn554, but these isolates showed distinct gene arrangements (array H and J, respectively). Clonally related OptrA-producing isolates were detected in Panama in 2011 (CC103) and were detected in Mexico (CC480) and Guatemala (CC256) in 2016 ( Table 3 Enterococcus linezolid resistance mechanisms JAC Table 3 . (Table 3 ). The fer gene encoding ferredoxin-NADP reductase (4Fe-2S ferredoxin iron-sulphur binding domain protein) was present downstream of optrA in 13 isolates. OptrA sequences in 18/26 isolates showed minor differences compared with the index sequence (plasmid pE349 from E. faecalis 19 GenBank accession number KP399637); eight variants, including those described by Cui et al., 34 were noted (Table 3) . Three alteration combinations not described by Cui et al. 34 were noted in Sweden/France (Y176D; identical to Streptococcus suis; GenBank accession number WP_099810410), Thailand (G40D, T481P; identical to GenBank accession number WP_002415370) and Panama (K3E, Y176D, G393D, I622M; novel combination).
All but one OptrA-producing E. faecalis from Sweden carried erm(B); dfr(G) was present in 18/26 and dfr(D) in 1/26 isolates. The majority of isolates (16/26) carried tet(L) and tet(M) and 5/26 isolates had tet(L) (2 isolates) or tet(M) (3 isolates) alone (Table 3 ). The cfr gene in the E. faecalis isolate from Thailand (2010) was embedded in an IS256-like structure with a chromosomal genetic context (tnp-aacA/aphD-IS256 like-orf-cfr) identical to S. epidermidis isolated in Tempe (Arizona) (GenBank accession number JX910899). cfr(B) in isolates from Panama showed a genetic context that was 98% identical to the isolate reported in E. faecium from New Orleans 18 (GenBank accession number KR610408).
Discussion
This study shows a low prevalence of enterococcal isolates nonsusceptible to linezolid (0.38%) and resistance mechanisms to oxazolidinones seem to have become distinct between E. faecalis and E. faecium. A previous review reported 23S rRNA alterations (G2576T) as the main resistance mechanism in both E. faecalis and E. faecium, especially in the USA. 16 However, this review described several E. faecalis isolates, mostly from countries other than the USA, where mechanisms of oxazolidinone resistance were not detected. Further investigations detected the presence of optrA in these isolates, which are described here. The study shows that optrA has now become more prevalent than the presence of 23S rRNA alterations in E. faecalis and the sole oxazolidinone resistance mechanism among isolates from 2014 to 2016.
Alterations in L3 and L4 proteins remained rare in Enterococcus spp.; however, six E. faecalis isolates in this set showed an L4 (F101L) alteration and one E. faecium displayed an L3 (K95T) alteration. The significance of these mutations remains unknown as these were always associated with another established linezolid resistance mechanism (Table 2 ) and also observed in linezolidsusceptible isolates.
34 Cfr(B) seems to be emerging in Enterococcus spp. and this study reports it from E. faecalis isolates for the first time. The cfr or cfr(B) genes were always associated with another linezolid resistance mechanism in E. faecalis (optrA) and E. faecium (G2576T) ( Table 2) , so it is not clear if cfr confers linezolid resistance in Enterococcus spp. We showed that cfr(B) confers a resistance phenotype similar to cfr in an S. aureus background; 18 however, its relevance in Enterococcus spp. has not been clearly defined and 23S rRNA alterations remain the main linezolid resistance mechanism in E. faecium. 22, 40 Isolates from China, Sweden, Ireland and the USA showed an optrA gene context similar to the plasmid structures described from China, 19, 39 with 452115 (China) and 441341 (Sweden) sequences showing 99% identity to pE349. These genetic contexts Enterococcus linezolid resistance mechanisms JAC were also similar to those reported in isolates from Poland and Colombia. 25, 26 The fexA gene was upstream of optrA in 13 isolates, albeit with variations between the arrays. E. faecalis isolates 739884 (China) and 912300 (USA) showed an identical optrA genetic context (array F), which was previously described in an isolate recovered from a pig (ST59; CC59) carrying p10-2-2. 39 Isolate 529360 (China; array B) showed IS1216 tnp bracketing optrA in a configuration most similar to that observed for pFX13 documented Deshpande et al.
in an isolate from a pig in China. The optrA gene context beyond the IS1216 element for isolates from Guatemala was distinct compared with any reports thus far, which included Tn551.
Isolates with chromosomally located optrA showed distinct array structures: G (Thailand), H (Taiwan) and J (France). E. faecalis 599799 from Thailand had optrA flanking regions displaying high homology with those noted for human isolates E016 and E079 previously reported from China. 39 The optrA array for isolate 973450 from France was identical to isolate G20 (human isolate) from China and was flanked by Tn558 (He et al.
39
). While this isolate showed hybridization signals on plasmid and chromosomal DNA bands, distinct optrA gene arrays could not be identified. All chromosomal optrA had flanking sequences containing the putative transcriptional regulator araC. 27 Finally, this study reports the global dissemination of optrA-carrying E. faecalis recovered from patients in countries beyond the Asia-Pacific region. E. faecalis isolates carrying optrA showed a very diverse genetic background. Interestingly, isolates belonging to the same CC were detected in distinct geographical regions. Also, isolates from Ireland with distinct genetic backgrounds had a similar optrA context, indicating plasmid dissemination. From the gene array analysis, it was evident that a great degree of genetic rearrangement is taking place as optrA spreads across the globe; the core genetic elements remaining similar, their positions in the array are divergent in isolates from different geographical locations. These results indicate the potential for dissemination and warrant constant surveillance for monitoring purposes. Although the majority of optrA genes were found in E. faecalis so far, this gene has also been documented in S. sciuri, E. faecium and other Gram-positive organisms, [21] [22] [23] [24] 34 and in in vitro transfer to different species. 25 Therefore, it is important to monitor the emergence and spread of this resistance determinant at a local and regional level, especially due to the potential for E. faecalis to serve as a reservoir for spreading optrA to MDR pathogens (i.e. E. faecium).
